RFC1 and cancer: Although merely an initial step, our results are encouraging as the presence of RFC1 in inner BRB may be exploited for targeted drug delivery such as RFC1-targeted nanodrugs, folate conjugated nanodrugs or even clinically widely used RFC1 substrate, methotrexate, can be exploited not only in cancer, but in diseases like ischemia.